🇺🇸 FDA
Pipeline program

MAb-3F8

3F8-NB-201

Phase 2 mab terminated

Quick answer

MAb-3F8 for Primary Refractory Neuroblastoma is a Phase 2 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Primary Refractory Neuroblastoma
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials